Regenerative Therapy

Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.
Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, Kawa K, Koike K, Tauchi H, Kajiwara M, Hara T, Kato S; Japanese Cord Blood Bank Network.
Department of Paediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan.
“Umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between …

“Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis.”
Clin Pharmacol Ther. 2010 Jun;87(6):679-85
Rice CM et al.
SourceInstitute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, UK.
“In this phase I study, we assessed the safety and feasibility of intravenous, autologous bone marrow (BM) cell therapy, without immunosuppressive preconditioning, in six patients with clinically definite, relapsing-progressive multiple sclerosis (MS)”
“The lack of serious adverse effects and the suggestion of a beneficial effect in this …

The most significant case for disease eradication after adoptive cell therapy is the TIL treatment.
A recent review summarizes the clinical data: Nat Rev Clin Oncol. 2011 Aug 2. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Rosenberg SA; Medscape.
“Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating lymphocytes results in objective cancer regression in 49-72% of patients with metastatic melanoma. In a pilot trial combining cell transfer with a maximum lymphodepleting regimen, …

Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan
Patients with  severe combined immunodeficiency (SCID, n = 40), Wiskott–Aldrich syndrome (WAS, n = 23), chronic granulomatous disease (n = 7), severe congenital neutropaenia (SCN, n = 5) and other immunodeficiencies (n = 13) treated with unrelated umbilical cord blood.
Source: Br J Haematol. 2011 May 14
http://www.ncbi.nlm.nih.gov/pubmed/21569009

Amyotrophic Lateral Sclerosis (ALS) – Clinical Updates Review
Keren Shternhall PhD
Introduction
Amyotrophic lateral sclerosis (ALS- known also as Lou Gehrig’s disease) is one of the most common neurodegenerative diseases of the motor neuron system. ALS is a rapidly progressive fatal neurological disorder that affects nerve cells in the brain and the spinal cord (called “motor neurons”) which are responsible for controlling voluntary muscles.
 The disease is characterized by degeneration and death of motor neurons that leads to miscommunication …

“Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases”
36 patients with chronic end-stage hepatitis C-induced liver disease and 12 with end-stage autoimmune liver disease. For all patients, granulocyte colony-stimulating factor was administered to mobilize their hematopoietic stem cells. Following leukapheresis, CD34(+) stem cells were isolated, amplified, and partially differentiated in culture, then reinjected into each subject via their hepatic artery or portal vein.
The results suggest that autologous CD34(+) stem cell transplantation …

Treatment of children with severe aplastic anemia with allogeneic cord blood stem cells transplantation.
“ This result suggests that CBT using optimal conditioning regimens can be a salvage treatment for patients without a suitable bone marrow donor and warrants further prospective studies.”
Reported in :
J Pediatr Hematol Oncol. 2010 Nov 18.  Jaing TH et al.
Cord Blood Transplantation in Children With Relapsed or Refractory Severe Aplastic Anemia.
http://www.ncbi.nlm.nih.gov/pubmed/21088620
Mackay Memorial Hospital, Taipei, Taiwan.

Case report on treatment of spinal injury with non related (allogeneic) stem cells. Reported in International Archives of Medicine on December 2010. 
Ichim et al. International Archives of Medicine 2010, 3:30
http://www.intarchmed.com/content/pdf/1755-7682-3-30.pdf
Cell combination for treatment composed of CD34+ cord blood derived stem cells and mesenchymal progenitor cells derived from cord tissue. Technology developed by Medistem Inc. San Diego, USA.  http://www.medisteminc.com/

Article in New England Journal of Medicine describing a pilot clinical study for treatment of patients with recessive dystrophic epidermolysis bullosa with allogeneic bone marrow transplantation. Dystrophic epidermolysis bullosa is an incurable, often fatal skin blistering disease caused by mutations in the gene encoding for type VII collagen. Seven children who had recessive dystrophic epidermolysis bullosa were treated with immunomyeloablative chemotherapy and allogeneic stem-cell transplantation. Increased C7 deposition and a sustained presence of donor cells …

Treatment of patients with advanced multiple sclerosis by intrathecal injection of ex-vivo expanded autologous bone marrow derived mesenchymal stem cells.  Assessment at 3-6 months revealed Expanded Disability Scale Score (EDSS) improvement in 5/7, stabilization in 1/7, and worsening in 1/7 patients.
J Neuroimmunol. 2010 Aug 20.
“Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study.”
Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan …